BRPI0919414A2 - Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio - Google Patents
Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênioInfo
- Publication number
- BRPI0919414A2 BRPI0919414A2 BRPI0919414A BRPI0919414A BRPI0919414A2 BR PI0919414 A2 BRPI0919414 A2 BR PI0919414A2 BR PI0919414 A BRPI0919414 A BR PI0919414A BR PI0919414 A BRPI0919414 A BR PI0919414A BR PI0919414 A2 BRPI0919414 A2 BR PI0919414A2
- Authority
- BR
- Brazil
- Prior art keywords
- hif
- interaction
- peptides
- 1alfa
- cbp
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 title 1
- 239000001257 hydrogen Substances 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 abstract 3
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 abstract 2
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 abstract 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 abstract 2
- 108010040163 CREB-Binding Protein Proteins 0.000 abstract 1
- 102100021975 CREB-binding protein Human genes 0.000 abstract 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 abstract 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 abstract 1
- 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9819308P | 2008-09-18 | 2008-09-18 | |
| PCT/US2009/057592 WO2010033879A2 (en) | 2008-09-18 | 2009-09-18 | Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0919414A2 true BRPI0919414A2 (pt) | 2017-07-11 |
Family
ID=42040175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919414A BRPI0919414A2 (pt) | 2008-09-18 | 2009-09-18 | Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9399666B2 (https=) |
| EP (1) | EP2344520B1 (https=) |
| JP (2) | JP2012503013A (https=) |
| CN (1) | CN102216322A (https=) |
| AU (1) | AU2009293020A1 (https=) |
| BR (1) | BRPI0919414A2 (https=) |
| CA (1) | CA2737614A1 (https=) |
| ES (1) | ES2446249T3 (https=) |
| WO (1) | WO2010033879A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008061192A2 (en) * | 2006-11-15 | 2008-05-22 | Dana-Farber Cancer Institute, Inc. | Stabilized maml peptides and uses thereof |
| CN105061577A (zh) | 2006-12-14 | 2015-11-18 | 爱勒让治疗公司 | 双巯基大环化系统 |
| ES2398310T3 (es) | 2007-02-23 | 2013-03-15 | Aileron Therapeutics, Inc. | Péptidos macrocíclicos unidos a triazol |
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| US9399666B2 (en) | 2008-09-18 | 2016-07-26 | New York University | Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices |
| ES2666458T3 (es) | 2008-09-22 | 2018-05-04 | Aileron Therapeutics, Inc. | Macrociclos peptidomiméticos |
| EP2352507A4 (en) | 2008-11-24 | 2012-04-25 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES |
| WO2010083347A2 (en) | 2009-01-14 | 2010-07-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US20130072439A1 (en) | 2009-09-22 | 2013-03-21 | Huw M. Nash | Peptidomimetic macrocycles |
| KR20170058446A (ko) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| US8511577B2 (en) | 2011-02-24 | 2013-08-20 | Nest Labs, Inc. | Thermostat with power stealing delay interval at transitions between power stealing states |
| JP6239979B2 (ja) * | 2011-03-04 | 2017-11-29 | ニューヨーク・ユニバーシティ | Ｒａｓの調節因子としての水素結合代替大環状分子 |
| AR088392A1 (es) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| CN104066435A (zh) * | 2011-12-21 | 2014-09-24 | 纽约大学 | 蛋白水解抗性的氢键替代螺旋 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| EP2945631A4 (en) * | 2013-01-19 | 2016-06-29 | Univ New York | OLIGOOXOPIPERAZINE FOR THE REACTIVATION OF P53 |
| WO2014113792A1 (en) * | 2013-01-19 | 2014-07-24 | New York University | Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation |
| US20150065436A1 (en) * | 2013-09-03 | 2015-03-05 | University Of Southern California | INHIBITING INTERACTION BETWEEN HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES |
| SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| WO2018008984A1 (ko) * | 2016-07-05 | 2018-01-11 | 이화여자대학교 산학협력단 | 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6986881B1 (en) | 1999-06-04 | 2006-01-17 | Dana-Farber Cancer Institute, Inc. | Identification of compounds that modify transcriptional responses to hypoxia |
| GB0211920D0 (en) | 2002-05-23 | 2002-07-03 | Isis Innovations Ltd | Assay |
| WO2005118620A2 (en) * | 2004-05-27 | 2005-12-15 | New York University | Methods for preparing internally constraied peptides and peptidomimetics |
| ITMI20042477A1 (it) | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche |
| KR100860060B1 (ko) * | 2006-10-12 | 2008-09-24 | 한국과학기술연구원 | ＨＩＦ-１α Ｃ-말단 펩타이드와 ＣＢＰ 또는 ｐ３００단백질과의 결합을 정량분석하는 방법 및 상기 방법을이용한 단백질 복합체 형성을 저해하는 억제제의 스크리닝방법 |
| US9399666B2 (en) | 2008-09-18 | 2016-07-26 | New York University | Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices |
| AU2009294871A1 (en) * | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
-
2009
- 2009-09-18 US US13/119,108 patent/US9399666B2/en active Active
- 2009-09-18 WO PCT/US2009/057592 patent/WO2010033879A2/en not_active Ceased
- 2009-09-18 AU AU2009293020A patent/AU2009293020A1/en not_active Abandoned
- 2009-09-18 JP JP2011528020A patent/JP2012503013A/ja not_active Withdrawn
- 2009-09-18 EP EP09815315.8A patent/EP2344520B1/en not_active Not-in-force
- 2009-09-18 BR BRPI0919414A patent/BRPI0919414A2/pt not_active IP Right Cessation
- 2009-09-18 CN CN2009801461214A patent/CN102216322A/zh active Pending
- 2009-09-18 CA CA2737614A patent/CA2737614A1/en not_active Abandoned
- 2009-09-18 ES ES09815315.8T patent/ES2446249T3/es active Active
-
2014
- 2014-09-12 JP JP2014186970A patent/JP2015061833A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102216322A (zh) | 2011-10-12 |
| WO2010033879A2 (en) | 2010-03-25 |
| US9399666B2 (en) | 2016-07-26 |
| JP2012503013A (ja) | 2012-02-02 |
| AU2009293020A1 (en) | 2010-03-25 |
| US20110245175A1 (en) | 2011-10-06 |
| ES2446249T3 (es) | 2014-03-06 |
| CA2737614A1 (en) | 2010-03-25 |
| EP2344520A4 (en) | 2012-03-14 |
| EP2344520A2 (en) | 2011-07-20 |
| EP2344520B1 (en) | 2013-11-13 |
| JP2015061833A (ja) | 2015-04-02 |
| WO2010033879A3 (en) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919414A2 (pt) | Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio | |
| Shah et al. | Cdk5 activity in the brain–multiple paths of regulation | |
| UY31067A1 (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
| Tönges et al. | Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease | |
| Ip et al. | Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management | |
| BRPI0520669A2 (pt) | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina | |
| Ferraguti et al. | Nerve growth factor and the role of inflammation in tumor development | |
| Teo et al. | Brain beta-catenin signalling during stress and depression | |
| Leite et al. | Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders | |
| CO6551721A2 (es) | Moduladores de cinasa novedosos | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
| ECSP088852A (es) | Azolopirimidinas como inhibidores de la actividad canabinoidea 1 | |
| BRPI0508931A (pt) | ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
| ECSP10010042A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| BRPI0606256A2 (pt) | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos | |
| BR112015023386A8 (pt) | composições e métodos para alterar os níveis de colesterol. | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
| CL2007002635A1 (es) | Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion. | |
| DK1766077T3 (da) | Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse | |
| GT200700004A (es) | Usos terapéuticos de inhibidores rtp801 | |
| X Sureda et al. | Antiapoptotic drugs: a therapautic strategy for the prevention of neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |